Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma ( com>sarikian@biovest.com or Accenti...)

(Date:12/2/2008)...ire/ -- Horizon Therapeutics, Inc., a,privately h...t two pivotal,Phase 3 trials evaluating its lead ...ll primary endpoints. HZT-501, a novel, proprietar...ofen and famotidine, demonstrated a,statistically...roidal,anti-inflammatory drug (NSAID)-induced upp...

(Date:12/1/2008)...c. 2 A study has found ...chnique for imaging the breast, is not affected by...s, two factors that limit the effectiveness of sta...ults will be presented today at the annual meeting...A). , , "The ability of PEM to detect canc...

(Date:12/1/2008).../ -- S*BIO Pte Ltd today announced the initiation ...and orally-active JAK2 inhibitor, in leading medic...idiopathic myelofibrosis (CIMF). , , The t...bility of SB1518 in patients with CIMF and is expe... of the study will assess the safety profile and e...

(Date:12/1/2008)...1 gene is a two-way switch that, if turned off, ca...d so that they lose their identity and become more...Tenn., Dec. 1 Scientis...iscovered that a certain differentiated cell type ...s the constant expression of a gene called Prox1 ...

Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2 Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3 Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4 New Mammography Technology Effective in Detecting Breast Cancer 2 New Mammography Technology Effective in Detecting Breast Cancer 3 New Mammography Technology Effective in Detecting Breast Cancer 4 S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2 S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3 Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2 Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3 Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 1 Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 2 SI International Awarded 244 Million Army HRsolutions Task Order 3781 1 SI International Awarded 244 Million Army HRsolutions Task Order 3781 2 SI International Awarded 244 Million Army HRsolutions Task Order 3781 3 Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1 Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2 CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 1 CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 2 CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 3 CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 4

[0] Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints [1] New Mammography Technology Effective in Detecting Breast Cancer [0] S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis [0] Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity

...SINESS WIRE)--Apr 30, 2007 - CollaGenex,Pharmaceut...ew,report in the May 2007 issue of the Journal of ... randomized phase III clinical trials,demonstrate...e,doxycycline (Oracea(R), 40-mg doxycycline, USP c... has concluded these studies,establish the first i...

...cal Use Approval and Insurance Coverage Varies,Gre...R, N.Y. - April 30, 2007-- Most U.S. adults suppor...edures that can,impact people,s quality of life, i...ization, drugs to treat erectile,dysfunction and i...majorities also believe these types of treatments ...

Other Medicine Technology:Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2 Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3 Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4 Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 2 Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 3 Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 4

Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance

(Date:12/2/2008)...ents Will Double by 2017, According to a New Repor...., Dec. 2 Decision Resources, one ... for pharmaceutical and healthcare issues, finds t...-Cilag,s Stelara and Abbott/Eisai,s Humira, will d...to more than double to nearly $5 billion over the ...

(Date:12/2/2008)...estimates that 1500 lives,could potentially be sa...ed,mortality rates (RAMR) for Coronary Artery Byp...pitals with the lowest RAMR. The same study also f... than men regardless of,performance ranking, but ....,The study ranked US hospitals conducting CABG s...

(Date:12/2/2008)...Mylan Inc. (NYSE: MYL ) today,announced that it...ave entered,into a settlement agreement with Nova...vartis International AG related to Letrozole Table..., Mylan,s Vice Chairman and CEO Robert J. Co...ed this agreement, which demonstrates our ability ...

(Date:12/2/2008)..., Dec. 2 ,Attainia and The Nationa...,will deploy Attainia,s suite of web-based budget...within the United Kingdom. , "NHSSC has mov...ns for the,Hospital trusts in the United Kingdom,...recognize that NHSSC is building one of the best p...

Breaking Medicine News(10 mins):Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2 Health News:New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals 2 Health News:New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals 3 Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2 Health News:The National Health Service and Attainia Move to Modernize Medical Capital Equipment Budgeting and Planning for the United Kingdom 2

[0] Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 [0] New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals [0] Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity [0] The National Health Service and Attainia Move to Modernize Medical Capital Equipment Budgeting and Planning for the United Kingdom

...pping up their efforts to combat a deadly outbreak...e highly// contagious disease could spread even mo... annual migration period within the region. Since... died and 8,557 cases have been recorded across ni...

...hat computer based therapy will be available for p...//. This will be available to all patients in Engl...er and Beating the blues have been designed as the...s medication. However, health experts have warned ...

...R vaccine is improving but is still below the targ... olds// are vaccinated in 2006 as against 89.9% of..., 95% should be vaccinated to prevent the general ... Though the ministers lauded the ascending trend i...

...d news. His colon cancer, which was treated two y...ted with chemotherapy in 2005 after doctors remove...of tumors that could be metastatic. Yet after rece...lvic area, doctors discovered additional tumors in...

Other Medicine News:Health News:West African Meningitis Outbreak Sparks Warning from UN Aid Agencies 2 Health News:Computer Based Therapy For Depression 2 Health News:White House Press Secretary to Battle Second Round of Colon Cancer 2

West African Meningitis Outbreak Sparks Warning from UN Aid Agencies Computer Based Therapy For Depression Children Receiving MMR Vaccine Still Below Target White House Press Secretary to Battle Second Round of Colon Cancer

Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog

Liquichek Hematology-16 Control is specifically designed for use on most hematology analyzers that measure up to 16 parameters and 3-part white blood cell differentials. This trilevel control can be

Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology.

Amplichek CT/GC Controls are liquid controls designed to monitor the precision of test procedures that detect Chlamydia trachomatis and Neisseria gonorrhoeae. Since they are specimen specific, they c

Medicine Products:

Lyphochek Hemoglobin A2 Control Liquichek Hematology-16 Control Liquichek Hematology Control (C)Amplichek CT/GC Controls

( com>sarikian@biovest.com or Accenti...)Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma,Health